Pharmaceutical Market Europe • May 2025 • 44
APPOINTMENTS
Sanofi
Chris Corsico
Sanofi has appointed Chris Corsico as global head of development. Corsico brings extensive industry experience to his latest role, having most recently served as senior vice president, head of development at GSK. Prior to joining GSK over six years ago, Corsico served as chief medical officer at Boehringer Ingelheim. He held a variety of positions over more than two decades at Boehringer, originally joining the company as associate director, drug surveillance and information, before steadily climbing through the ranks to roles such as head of drug surveillance and information, vice president of drug regulatory affairs, corporate senior vice president of quality, regulatory, pharmacovigilance and epidemiology, as well as corporate senior vice president of medicine.
Scholar Rock
David Hallal
Scholar Rock has appointed David Hallal as chief executive officer. Hallal, who is already chairman of Scholar Rock's board, brings extensive experience to the role. He was previously chief executive officer of Alexion Pharmaceuticals, after serving as the company’s chief commercial officer and chief operating officer. He has also held roles at Biogen and Amgen.
Creyon Bio
Serge Messerlia
Creyon Bio has appointed Serge Messerlia as chief executive officer. Messerlia, who joined the company as executive chairman and acting chief executive officer last year, brings significant industry experience to the role. He previously served as chief executive officer of Teon Therapeutics and president of Janssen Oncology, a Johnson & Johnson company.
Hansa Biopharma
Renée Aguiar-Lucander
Hansa Biopharma has appointed Renée Aguiar-Lucander as chief executive officer. Aguiar-Lucander has extensive experience in both the biopharmaceutical and financial sectors. She takes on the role after most recently serving as chief executive officer of Calliditas Therapeutics. Prior to this, she held senior roles in funds such as Omega Funds and 3i Group.
ProQR Therapeutics
Cristina Lopez Lopez
ProQR Therapeutics has appointed Cristina Lopez Lopez as chief medical officer. Lopez takes on the role after serving as global head of neurodegeneration at Johnson & Johnson. Prior to this, she was vice president, global head of biomarkers and translational technologies at Roche, and vice president, global head of neurodegeneration and neuromuscular at Novartis.
Veranova
Scott Zugel
Veranova has appointed Scott Zugel as global vice president of analytical research development operations. Zugel holds over 25 years of experience in the chemical and pharmaceutical industries, and joins Veranova after serving as head of analytical development USA at Takeda Pharmaceuticals. He also previously held several positions at Pfizer.
Scholar Rock
Akshay Vaishnaw
Scholar Rock has appointed Akshay Vaishnaw as president of research and development. Vaishnaw has over 25 years of biotechnology industry experience and previously served in positions of increasing responsibility across research and development at Alnylam Pharmaceuticals, culminating in his role as president. He also previously held various positions at Biogen.
Scholar Rock
R Keith Woods
Scholar Rock has appointed R Keith Woods as chief operating officer. Woods holds over three decades of biopharmaceutical industry experience and most recently served as chief operating officer of argenx. Prior to this, he was senior vice president of North American operations for Alexion Pharmaceuticals, and held various roles at Roche, Amgen and Eisai.
MOMA Therapeutics
Neil Lineberry
MOMA Therapeutics has appointed Neil Lineberry as head of corporate development. Lineberry joins MOMA from Takeda Pharmaceuticals, where he most recently served as vice president, global programme lead, oncology therapeutics area. He served in multiple roles over ten years at Takeda and also previously held positions at Navigant and Leerink Partners.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services